← Back to headlines
Genentech's Tecentriq Approved for Bladder Cancer Indication
Genentech has received approval for a new bladder cancer indication for its drug, Tecentriq, expanding its therapeutic use.
15 May, 18:00 — 15 May, 18:00
Sources
Showing 1 of 1 sources
